NasdaqGS:PGENBiotechs
Precigen (PGEN) Is Up 11.9% After PAPZIMEOS’ Launch Shifts Focus Toward Commercial Revenue Model
For the full year 2025, Precigen, Inc. reported revenue of US$9.68 million compared to US$3.93 million in 2024, while net loss widened to US$250.64 million and loss per share from continuing operations increased to US$1.37.
Despite the larger loss, Precigen’s first FDA-approved therapy PAPZIMEOS for adult recurrent respiratory papillomatosis, broad label, emerging standard-of-care status, and upcoming permanent J-code together mark a shift toward a commercial revenue model with growing...